Neurocrine Biosciences
NBIX
$93.39
Share price
-0.68%
Change (1 day)
-4.02%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Market capitalization of Neurocrine Biosciences (NBIX)
Market cap: $9.11 Billion
As of June 2023 Neurocrine Biosciences has a market cap of $9.11 Billion. This makes Neurocrine Biosciences the world's 1624th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Neurocrine Biosciences from 2001 to 2023
End of year Market Cap
| Year | Market cap | Change |
|---|---|---|
| 2023 | $9.11 B | -20.64% |
| 2022 | $11.48 B | 42.11% |
| 2021 | $8.07 B | -9.78% |
| 2020 | $8.95 B | -9.71% |
| 2019 | $9.91 B | 52.97% |
| 2018 | $6.48 B | -5.57% |
| 2017 | $6.86 B | 104.23% |
| 2016 | $3.36 B | -31.11% |
| 2015 | $4.87 B | 185.67% |
| 2014 | $1.70 B | 171.56% |
| 2013 | $0.62 B | 26.57% |
| 2012 | $0.49 B | 5.82% |
| 2011 | $0.46 B | 12.02% |
| 2010 | $0.41 B | 250.42% |
| 2009 | $0.11 B | -3.12% |
| 2008 | $0.12 B | -28.92% |
| 2007 | $0.17 B | -56.01% |
| 2006 | $0.39 B | -83.04% |
| 2005 | $2.32 B | 29.33% |
| 2004 | $1.80 B | -6.48% |
| 2003 | $1.92 B | 37.56% |
| 2002 | $1.40 B | -10.09% |
| 2001 | $1.55 B |
End of Day market cap according to different sources
On Jun 9th, 2023 the market cap of Neurocrine Biosciences was reported to be:
$9.11 Billion
$9.11 Billion
$9.11 Billion
$9.11 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $219.99 B | 2,314.24% | 🇺🇸 USA |
 AbbVie ABBV | $243.78 B | 2,575.33% | 🇺🇸 USA |
 Eli Lilly LLY | $423.41 B | 4,546.51% | 🇺🇸 USA |
 Repligen
RGEN | $9.03 B | -0.90% | 🇺🇸 USA |
 Athersys ATHX | $20.87 M | -99.77% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | $0.99 B | -89.06% | 🇺🇸 USA |
 Palatin Technologies PTN | $26.04 M | -99.71% | 🇺🇸 USA |
 Royalty Pharma RPRX | $14.76 B | 62.06% | 🇬🇧 UK |